Astmabehandling i almen praksis

Victor Behrendt; Ole Hilberg; Vibeke Backer; Charlotte Suppli Ulrik; Niels Bjerring; Anders Løkke

Astmabehandling i almen praksis

Victor Behrendt, Ole Hilberg, Vibeke Backer, Charlotte Suppli Ulrik, Niels Bjerring, Anders Løkke

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

4 Downloads (Pure)

Abstract

This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.

Bidragets oversatte titel	Asthma treatment in general practice
Originalsprog	Dansk
Artikelnummer	V03210221
Tidsskrift	Ugeskrift for Læger
Vol/bind	184
Udgave nummer	11
Antal sider	8
ISSN	0041-5782
Status	Udgivet - 30. maj 2022

Emneord

Administration, Inhalation
Adrenal Cortex Hormones/therapeutic use
Adult
Anti-Asthmatic Agents/adverse effects
Asthma/drug therapy
Drug Therapy, Combination
Ethanolamines/therapeutic use
Formoterol Fumarate/therapeutic use
General Practice
Humans

Dokumenter og links

Open Access VersionForlagets udgivne version, 740 KBLicens: CC BY-NC-ND

https://ugeskriftet.dk/videnskab/astmabehandlingi-almen-praksisLicens: CC BY-NC-ND

Citationsformater

@article{bc864fe50ac54f13be0434eca4a06877,

title = "Astmabehandling i almen praksis",

abstract = "This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.",

keywords = "Administration, Inhalation, Adrenal Cortex Hormones/therapeutic use, Adult, Anti-Asthmatic Agents/adverse effects, Asthma/drug therapy, Drug Therapy, Combination, Ethanolamines/therapeutic use, Formoterol Fumarate/therapeutic use, General Practice, Humans",

author = "Victor Behrendt and Ole Hilberg and Vibeke Backer and Ulrik, {Charlotte Suppli} and Niels Bjerring and Anders L{\o}kke",

year = "2022",

month = may,

day = "30",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "11",

}

TY - JOUR

T1 - Astmabehandling i almen praksis

AU - Behrendt, Victor

AU - Hilberg, Ole

AU - Backer, Vibeke

AU - Ulrik, Charlotte Suppli

AU - Bjerring, Niels

AU - Løkke, Anders

PY - 2022/5/30

Y1 - 2022/5/30

N2 - This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.

AB - This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.

KW - Administration, Inhalation

KW - Adrenal Cortex Hormones/therapeutic use

KW - Adult

KW - Anti-Asthmatic Agents/adverse effects

KW - Asthma/drug therapy

KW - Drug Therapy, Combination

KW - Ethanolamines/therapeutic use

KW - Formoterol Fumarate/therapeutic use

KW - General Practice

KW - Humans

M3 - Tidsskriftartikel

C2 - 35023469

AN - SCOPUS:85131439238

SN - 0041-5782

VL - 184

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 11

M1 - V03210221

ER -

Astmabehandling i almen praksis

Abstract

Emneord

Dokumenter og links

Fingeraftryk

Citationsformater